aripiprazole has been researched along with apomorphine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Pettersson, F; Pontén, H; Sonesson, C; Waters, N; Waters, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bienkowski, P; Bucki, A; Jastrzębska-Więsek, M; Kazek, G; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Siwek, A; Śniecikowska, J; Wasik, A; Wesołowska, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hirose, T; Kikuchi, T; Miwa, T; Morita, S; Oshiro, Y; Tottori, K; Uwahodo, Y | 1 |
| Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y | 1 |
| Ge, HX; Jiang, ZZ; Ni, SL; Wang, LC | 1 |
| Araki, H; Hirose, T; Kikuchi, T; Mori, T; Nakai, S; Stark, A | 1 |
| Freichel, C; Künnecke, B; Maco, M; Moreau, JL; Nordquist, RE; Riemer, C; Risterucci, C; Spooren, W; von Kienlin, M | 1 |
| Araki, H; Kawasaki, H; Kohnomi, S; Suemaru, K | 1 |
| Arnt, J; Dahan, L; Haddjeri, N; Hertel, P; Husum, H; Mnie-Filali, O | 1 |
| Calas, AG; Goursaud, S; Hermans, E; Jeanjean, AP; Koener, B; Maloteaux, JM; Van De Stadt, M | 1 |
| Hoenicka, J; Jiménez-Arriero, MÁ; Martín-Palanco, NG; Palomo, T; Ponce, G; Quiñones-Lombraña, A; Rubio-Solsona, E | 1 |
| Gill, KM; Grace, AA; Sonnenschein, SF | 1 |
1 review(s) available for aripiprazole and apomorphine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for aripiprazole and apomorphine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding, Competitive; Cell Line; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Ligands; Male; Models, Chemical; Molecular Structure; Motor Activity; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indoles; Ligands; Male; Models, Molecular; Molecular Structure; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Swimming | 2015 |
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Catalepsy; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Male; Mice; Mice, Inbred ICR; Motor Activity; Oxidopamine; Piperazines; Presynaptic Terminals; Quinolones; Radioligand Assay; Rats; Reserpine; Spiperone; Stereotyped Behavior; Synapses; Tritium | 1995 |
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine Antagonists; GABA Modulators; Male; Mice; Mice, Inbred ICR; Molecular Structure; Piperazines; Quinolones; Rats; Stereotyped Behavior; Structure-Activity Relationship | 1998 |
Synthesis and bioactivity of aripiprazole derivatives.
Topics: Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Female; Indicators and Reagents; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Mice, Inbred ICR; Piperazines; Quinolones; Receptors, Dopamine; Sex Characteristics; Spectrophotometry, Infrared; Stereotyped Behavior | 2006 |
The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Conditioning, Classical; Dopamine Agents; Drug Interactions; Inhibition, Psychological; Ion Channel Gating; Male; Neural Inhibition; Piperazines; Quinolones; Rats; Rats, Wistar; Reaction Time; Receptors, Dopamine D2; Reflex, Startle | 2008 |
Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
Topics: Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Data Interpretation, Statistical; Dopamine Agonists; Hallucinogens; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Motor Activity; N-Methylaspartate; Piperazines; Postural Balance; Psychoses, Substance-Induced; Quinolones; Rats; Rats, Sprague-Dawley; Reflex, Startle; Serotonin Receptor Agonists | 2008 |
Effect of aripiprazole on 5-HT2 receptor-mediated wet-dog shake responses and disruption of prepulse inhibition in rats.
Topics: Amphetamines; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Behavior, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Models, Animal; Piperazines; Quinolones; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine; Reflex, Startle; Serotonin Receptor Agonists; Stereotyped Behavior; Time Factors | 2008 |
Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Apomorphine; Aripiprazole; Benzoxazoles; Dopamine; Dopamine D2 Receptor Antagonists; Electroshock; Haloperidol; Male; Neurons; Piperazines; Pyridines; Quinolones; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Ultrasonics; Ventral Tegmental Area; Vocalization, Animal | 2009 |
Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
Topics: Animals; Apomorphine; Aripiprazole; Buffers; Catalepsy; Cell Membrane; Cerebral Cortex; Corpus Striatum; Domperidone; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Antagonism; Drug Partial Agonism; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Hippocampus; Male; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Stereotyped Behavior; Up-Regulation | 2011 |
The Addiction-Related Gene Ankk1 is Oppositely Regulated by D1R- and D2R-Like Dopamine Receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Aripiprazole; Brain; Down-Regulation; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Protein Serine-Threonine Kinases; Quinolines; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Tetrahydronaphthalenes; Up-Regulation | 2016 |
State-dependent effects of the D
Topics: Animals; Apomorphine; Aripiprazole; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopaminergic Neurons; Electroencephalography; Haloperidol; Male; Methylazoxymethanol Acetate; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Ventral Tegmental Area | 2019 |